Tokyo, Aug. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058691) titled 'Efficacy of imeglimin in stepping down from multiple daily insulin injection with DPP-4 inhibitor' on Aug. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Toho university school of medicine
Condition:
Condition - type 2 diabetes
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the insulin dosage reduction effect of adding imeglimin to patients treated with multiple daily insulin injection and DPP-4 inhibitor.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - Hospitalized patients who were treated adding imeglimin for more than 5 days on combination therapy with multiple daily insulin injection and DPP-4 inhibitors.
Key exclusion criteria - Type 1 diabetes
Patients who couldn't continue to take imeglimin for more than 5 days
Patients who have used drugs other than antidiabetic drugs that may cause fluctuations in blood glucose levels
Patients who had been using antidiabetic drugs other than insulin or DPP-4 inhibitors before or within 5 days after starting Imeglimin.
Patients who have had changes in their condition that may have led to fluctuations in blood glucose levels within 5 days after initiation of imeglimin.
Patients considered ineligible for the study.
Target Size - 30
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2024 Year 10 Month 30 Day
Date of IRB - 2024 Year 10 Month 30 Day
Anticipated trial start date - 2024 Year 11 Month 01 Day
Last follow-up date - 2025 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067093
Disclaimer: Curated by HT Syndication.
